

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. **(Currently amended)** A method of therapeutically downmodulating an autoimmune response in a subject comprising administering an isolated antigen binding portion of an anti-CD28 antibody that blocks signaling via CD28 to the subject such that an autoimmune response in the subject is downmodulated.
2. **(Original)** The method of claim 1, wherein the antigen binding portion is an scFv molecule or an Fab fragment.
3. **(Original)** The method of claim 1, wherein the antigen binding portion is humanized.
4. **(Original)** The method of claim 1, wherein the antigen binding portion is fully human.
5. **(Canceled)**
6. **(Currently amended)** The method of claim 1 ~~or 5~~, wherein the autoimmune response is mediated by CD4+ T cells.
7. **(Currently amended)** The method of claim 1 ~~or 5~~, wherein the autoimmune response is mediated by CD8+ T cells.
8. **(Currently amended)** The method of claim 1 ~~or 5~~, wherein the autoimmune response is type I diabetes.

9. **(Currently amended)** A method of therapeutically downmodulating an ongoing autoimmune response in a subject comprising administering an isolated antigen binding portion of an anti-CD28 antibody that blocks signaling via CD28 to the subject such that an ongoing autoimmune response in the subject is downmodulated.
10. **(Original)** The method of claim 9, wherein the antigen binding portion is a scFv molecule or an Fab fragment.
11. **(Original)** The method of claim 9, wherein the antigen-binding portion is humanized.
12. **(Original)** The method of claim 9, wherein the antigen-binding portion is fully human.
13. **(Canceled)**
14. **(Currently amended)** The method of claim 9 ~~or 13~~, wherein the autoimmune response is mediated by CD4+ T cells.
15. **(Currently amended)** The method of claim 9 ~~or 13~~, wherein the autoimmune response is mediated by CD8+ T cells.
16. **(Currently amended)** The method of claim 9 ~~or 13~~, wherein the autoimmune response is type I diabetes.
17. **(Currently amended)** A method of prophylactically downmodulating an autoimmune response in a subject comprising administering an isolated antigen binding portion of an anti-CD28 antibody that blocks signaling via CD28 to the subject such that an autoimmune response in the subject is downmodulated or delayed in its onset.
18. **(Original)** The method of claim 17, wherein the antigen binding portion is a scFv molecule or an Fab fragment.

19. **(Original)** The method of claim 17, wherein the antigen-binding portion is humanized.
20. **(Original)** The method of claim 17, wherein the antigen-binding portion is fully human.
21. **(Canceled)**
22. **(Currently amended)** The method of claim 17 ~~or 21~~, wherein the autoimmune response is mediated by CD4+ T cells.
23. **(Currently amended)** The method of claim 17 ~~or 21~~, wherein the autoimmune response is mediated by CD8+ T cells.
24. **(Currently amended)** The method of claim 17 ~~or 21~~, wherein the autoimmune response is type I diabetes.
25. **(New)** The method of claim 1, wherein the antigen binding portion is monovalent.
26. **(New)** The method of claim 9, wherein the antigen binding portion is monovalent.
27. **(New)** The method of claim 17, wherein the antigen binding portion is monovalent.